Physician profile
Karl Langberg
NPI 1285070730
$16,780.78
in general payments reported to CMS, 2019-2025
30 companies · $6,613 in 2025
The $6,613 reported for 2025 was more than what 91% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $364 · 2020: $14.54 · 2021: $215 · 2022: $243 · 2023: $666 · 2024: $8,666 · 2025: $6,613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Food and Beverage: $3,006 · Travel and Lodging: $38.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,900.00 |
| Food and Beverage | $3,006.04 |
| Travel and Lodging | $38.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $13,489.26 | 2024-2025 | Voquezna |
| Abbvie INC. | $1,039.70 | 2020-2025 | |
| Ardelyx, INC. | $360.31 | 2023-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $259.37 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $185.32 | 2022-2025 | Entyvio |
| Celgene Corporation | $169.34 | 2021-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $168.19 | 2019-2025 | |
| Madrigal Pharmaceuticals | $154.29 | 2025 | Rezdiffra |
| Novo Nordisk INC | $119.75 | 2019 | |
| Pfizer INC. | $108.94 | 2024-2025 | |
| Ironwood Pharmaceuticals, INC | $82.63 | 2021-2024 | Linzess |
| Lilly USA, LLC | $70.66 | 2024-2025 | Omvoh |
| Medtronic, INC. | $69.08 | 2025 | Barrx |
| Genzyme Corporation | $62.62 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $43.80 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $43.70 | 2023-2025 | Dupixent |
| Aimmune Therapeutics, INC. | $42.48 | 2024 | |
| Qol Medical, LLC | $39.84 | 2025 | Sucraid |
| Janssen Biotech, INC. | $35.17 | 2023-2025 | Stelara, Tremfya, Simponi |
| Organon LLC | $33.94 | 2023 | Hadlima |
| Cook Medical LLC | $28.57 | 2019 | |
| Ferring Pharmaceuticals INC. | $27.53 | 2023-2024 | Rebyota |
| Exact Sciences Corporation | $23.53 | 2024 | Cologuard Collection Kit |
| Digestive Care, INC. | $21.75 | 2025 | Pertzye |
| Braintree Laboratories, INC. | $20.00 | 2023 | Sutab |
| Pentax of America, INC. | $17.62 | 2023 | Pentax Medical |
| Gilead Sciences, INC. | $16.47 | 2025 | |
| Tempus Ai, INC | $16.38 | 2024 | Xt Cdx |
| Redhill Biopharma INC. | $16.13 | 2022 | |
| Nestle Healthcare Nutrition INC. | $14.41 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karl Langberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.